Related Experiment Video
Updated: Sep 9, 2025
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Increase in circulating GLP-1 following low FODMAP diet in irritable bowel syndrome patients
Umael Khan1, Ingeborg Brønstad1,2, Eline Margrete Randulff Hillestad3,4
1Section of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Background:
Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) as well as glucagon-like peptide-1 (GLP-1) have independently been implicated in irritable bowel syndrome (IBS) pathophysiology. However, there is a lack of studies that assess how low FODMAP diet affects circulating GLP-1 levels in IBS patients.
Methods:
Thirty patients with either diarrhea or mixed type IBS were recruited and undertook low FODMAP diet for 12 weeks. Plasma GLP-1 levels, IBS Severity Scoring System (IBS-SSS), body weight and FODMAP intake were assessed before and after the 12-week dietary intervention.
Key Results:
Following a low FODMAP diet, average IBS-SSS and body weight were reduced (p < 0.01) and plasma GLP-1 level was increased (p = 0.027).
Conclusion:
Our study indicates that a 12-week low FODMAP diet may increase plasma glucagon-like peptide-1 levels in IBS patients. The underlying mechanism for this increase remains to be understood.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...